
Opinion|Videos|September 3, 2024
The Importance of Serum Testosterone Levels With the Use of Androgen Receptor-Targeting Therapies
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Panelists discuss how the STAAR study (Stein, 2018) indicates that the micronized abiraterone formulation results in lower average serum testosterone levels in 25% of patients compared to 17% with the originator formulation, potentially influencing treatment selection.
Advertisement
Episodes in this series

- To what extent do average serum testosterone levels guide selection between abiraterone formulations?
- STAAR study: Average serum testosterone levels≤0.1 ng/dL occurred in 25% of patients treated with micronized formulation vs 17% of patients receiving the originator formulation.
Advertisement
Related to this article

The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.

Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.

The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.

Lorelei A. Mucci, ScD, MPH, discusses the evolving evidence surrounding diet, physical activity, and other lifestyle factors in prostate cancer care.

Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.

Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.

A randomized trial will test whether an app-guided, at-home PSA screening approach can improve prostate cancer screening among Black men.
Advertisement
Advertisement
Trending on Urology Times
1
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
2
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
3
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
4
Jonathan Harper, MD, on the importance of fluid intake for reducing stone recurrence
5

